Roger McIntyre

Dr. Roger McIntyre, a leading mental health expert in psychopharmacology, joins Dr. Andy Cutler to reflect on significant advances in the field this year. They dive into groundbreaking treatments for schizophrenia, discussing innovative drugs and their potential in improving cognitive and negative symptoms. The conversation also covers the complexities of prescribing anticholinergic medications and advancements in TMS therapy for adolescent depression. Insights on suicidality, mood disorders, and the interplay between sleep and mental health leave listeners with a deeper understanding of these crucial topics.

Dr. Roger McIntyre, Professor of Psychiatry at the University of Toronto, discusses the differentiation of normal 'low mood' from psychiatric conditions. The podcast covers historical subtypes of depression, DSM specifiers for major depressive disorder, epidemiology, neurophysiology, and treatment options.

Join Dr. Katherine Dahlsgaard, an expert in child social anxiety, as she shares innovative strategies like cognitive behavioral therapy for pediatric patients. Dr. Roger McIntyre discusses the fascinating link between inflammation, diet, and mental health, emphasizing the importance of nutrition in treating depression. Dr. Thomas Schwartz provides insights on sleep disorders, highlighting effective use of caffeine and melatonin for better rest. Together, they tackle vital topics that intertwine mental health, childhood anxiety, and lifestyle choices.

Dr. Roger S. McIntyre, a leading expert in treatment-resistant depression and bipolar disorder, joins Dr. Andrew Cutler to discuss the complexities of prescribing potentially unsafe drug combinations. They explore the intricacies of pharmacokinetics and pharmacodynamics, emphasizing the risks of polypharmacy. Key topics include the importance of monitoring drug interactions, the implications of anticholinergic medications, and the safety of stimulants in mood disorders. The conversation highlights guidelines for responsible prescribing and the challenges of managing treatment-resistant cases.

Dr. Roger McIntyre, a leading psychiatrist and pharmacologist from the University of Toronto, discusses the growing neuropsychiatric implications of Long COVID. He explores the links between neuroinflammation and symptoms like cognitive impairment and fatigue. The conversation delves into the complexities of treatment options, including innovative approaches like lithium orotate and personalized therapies. McIntyre also highlights the disparities in diagnosis and treatment, especially in minority populations, advocating for a nuanced understanding of this challenging condition.